Sector Expert: Alan Leong

BioWatch News

Image: Alan Leong

Alan Leong is the cofounder and CEO of BioWatch LLC. The company's services and monthly journal, BioWatch News, are for those who invest and have a fascination with seeing whatĺs next in the biotech industry. It features individual companies and also introduces readers to edgy topics and sectors. Past issues featured alopecia, metabolic syndrome, the future of biotech and pet meds. Before BioWatch, Leong was cofounder of Biotech Stock Research (BSR), a boutique service for life science investors. He published more than 1,500 pages for BSR and wrote more than 45 main feature stories, plus numerous alerts, company updates and annual reviews. Leong has also been an award-winning instructor within the University of Washington system, teaching courses in entrepreneurship, technology forecasting and early-stage investing.

Subscribe to
Streetwise Reports
Ask this Expert

Companies Commented On

  • Bellicum Pharmaceuticals Inc.
  • BioMarin Pharmaceuticals Inc.
  • Capricor Therapeutics
  • Celator Pharmaceuticals Inc.
  • Cipher Pharmaceuticals Inc.
  • ContraFect Corp.
  • ContraVir Pharmaceuticals Inc.
  • Gilead Sciences Inc.
  • Hansen Medical Inc.
  • Juno Therapeutics
  • Prothena Corp.
  • RepliCel Life Sciences Inc.
  • Resverlogix Corp.
  • Rexahn Pharmaceuticals Inc.
  • Seattle Genetics
  • Sorrento Therapeutics Inc.
  • Sunesis Pharmaceuticals Inc.


Recent Interviews

The Academic Approach to Biotech Stocks: Alan Leong of BioWatch News (1/20/16)
bluepetrihand630

Combining academic discipline with methodical due diligence, Alan Leong of BioWatch News undertakes a regimented review of each biotech and medtech stock he investigates. In some cases he will follow a company's clinical development program and data for years before he pulls the trigger and recommends a name. In this interview with The Life Sciences Report, Leong presents a number of names for investors' consideration. Many won't be mentioned in his usual write-ups: It's an early look at what's on his watch list and in his inbox. Each company carries its own risks, but every stock has a special growth story that could propel huge gains if data fall into place.

CAR T-Cell Therapeutics: Alan Leong of BioWatch Looks Beyond the Buzz for Solid Early-Stage Plays (9/9/15)
microscopeblue580

CAR T-cell therapies show amazing potential in treating blood cancers, but there's a lot of work to do before the cells are ready for commercialization. Alan Leong, senior analyst with BioWatch, tells The Life Sciences Report about the latest in CAR T-cell therapeutics and how some companies are hedging their bets by developing bispecific antibodies. He also describes the reality behind the growing excitement in regenerative medicine, and what investors should know about some very innovative, but often overlooked, small companies.

How Alan Leong of BioWatch News Keeps Successful Biotech Investing Simple (3/4/15)
scope580

Biotechnology can be daunting to comprehend, but understanding is critical to successful investment. BioWatch News Founder Alan Leong has a nose for growth names, and his goal is to make their technology platforms clear to investors who might not be able to make sense of peer-reviewed scientific literature but want the big upside that science promises. In this interview with The Life Sciences Report, Leong brings seven micro-cap names with massive potential to investors' attention.

Recent Quotes

"RP had successful proof of concept with RCH-01 with restoring hair."

The Life Sciences Report Interview with Alan Leong (1/20/16)
moreá>

"HNSN's systems should increase the precision and safety of the surgical procedures."

The Life Sciences Report Interview with Alan Leong (1/20/16)
moreá>

"CPHR is a long-term story for value investors as it improves revenue and margins."

The Life Sciences Report Interview with Alan Leong (1/20/16)
moreá>

"An approval of SNSS' vosaroxin in the EU would be the surprise upside to monitor."

The Life Sciences Report Interview with Alan Leong (1/20/16)
moreá>

"RNN is in full swing; 2016 is going to be an interesting year."

The Life Sciences Report Interview with Alan Leong (1/20/16)
moreá>

"We like CTRV's team, and we like the products."

The Life Sciences Report Interview with Alan Leong (1/20/16)
moreá>

"If RVX is successful with RVX-208, there is a lot of upside left."

The Life Sciences Report Interview with Alan Leong (1/20/16)
moreá>

"SNSS was encouraged by European Union regulatory staff to submit for approval of Qinprezo."

The Life Sciences Report Interview with Alan Leong (9/9/15)
moreá>

more comments

"CPXX's acute myeloid leukemia therapy shows superior delivery and uptake by cancer cells."

The Life Sciences Report Interview with Alan Leong (9/9/15)
moreá>

"When it goes head-to-head against tenofovir, CTRV's CMX157 is a slam dunk."

The Life Sciences Report Interview with Alan Leong (9/9/15)
moreá>

"RP is a very provocative, very interesting company."

The Life Sciences Report Interview with Alan Leong (9/9/15)
moreá>

"CTRV's experienced management team knows how to present well, and investors are responding."

The Life Sciences Report Interview with Alan Leong (3/4/15)
moreá>

"RP is going for a best-of-breed solution."

The Life Sciences Report Interview with Alan Leong (3/4/15)
moreá>

"Shiseido's investment in a collaboration with RP is a form of validation for the company."

The Life Sciences Report interview with Alan Leong (7/17/14)
moreá>

fewer comments


Due to permission requirements, not all quotes are shown.